Diabetes drug dorzagliatin under Long-Term safety watch
NCT ID NCT06263348
First seen Jul 10, 2026 · Last updated Jul 10, 2026
Summary
This study tracks the long-term safety of dorzagliatin, a drug for type 2 diabetes, in over 2,000 patients over 52 weeks. Researchers monitor side effects and how well the drug controls blood sugar. The goal is to ensure the drug remains safe for everyday use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dorzagliatin
- What this could lead to
- If successful, this study could confirm that dorzagliatin is safe for long-term use in managing type 2 diabetes.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Side effects may still emerge in larger populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE2DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
China-Japan Friendship Hospital
Beijing, Beijing Municipality, 100029, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a smart monitor help pregnant women with diabetes have healthier babies?
- Smart patch and coach app aim to tame diabetes in pregnancy
- Electric zaps to the gut could help control type 2 diabetes
- Calorie cut may unlock Liver's hidden power in diabetes
- Ear stimulation device shows promise for diabetic nerve pain
- New study asks: is this glucose monitor a Game-Changer for diabetes?